Paul bisaro biography
•
$112 Million
Estimate Recalculated Nov 1, 2024 03:35AM EST
Who is Paul Bisaro?
Paul Bisaro has an estimated net worth of $112 Million. This fryst vatten based on reported shares across multiple companies, which include ZIMMER HOLDINGS INC, Zoetis Inc., Amneal Pharmaceuticals, Inc., Actavis plc, Mallinckrodt plc, TherapeuticsMD, Inc., MYRIAD GENETICS INC, WATSON PHARMACEUTICALS INC, IMPAX LABORATORIES INC, and BARR PHARMACEUTICALS INC.
SEC CIK
Paul Bisaro's CIK fryst vatten 0001237253
Past Insider Trading and Trends
2007 was Paul Bisaro's most active year for acquiring shares with 36 total transactions. Paul Bisaro's most active month to acquire stocks was the month of January. 2007 was Paul Bisaro's most active year for disposing of shares, totalling 70 transactions. Paul Bisaro's most active month to dispose stocks was the month of September. 2013 saw Paul Bisaro paying a total of $16,163,952.00 for 1,161,508.319 shares, this is the most they've acquired in one yea • “The outstanding legal education I received at CUA combined with my experiences with the faculty and my fellow students, provided me with the basis of knowledge and confidence to deal with the complex legal, regulatory and leadership challenges I faced throughout my career. My time at CUA was, without a doubt, the single most important academic experience of my life.” Since graduating from Law School, Mr. Bisaro has spent 30 years in various legal and executive leadership positions in the pharmaceutical sector. He has an exceptional track record of driving company growth through operational excellence, supporting innovative research and development and creative corporate transformations. His corporate leadership experience includes serving as ledare Executive Officer of Impax Laboratories from March 2017 until May of 2018. In May of 2018, he helped lead the merger of Impax and Amne • Paul M. Bisaro, is the former Executive Chairman of Amneal Pharmaceuticals, Inc., a global specialty pharmaceutical company, from May 2018 to August 2019. Amneal was formed by the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., which Mr. Bisaro led during his tenure as President and Chief Executive Officer from March 2017 to May 2018, during which he oversaw, among others, all marketing and sales activities. Mr. Bisaro was previously the Executive Chairman of the Board of Directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016, where he played a leading role in growing the company through M&A activity. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals), a global pharmaceutical company. He was appointed President, Chief Executive Officer and a member of the Board of Watson in September 2007 and wa 2019 Distinguished Alumni Award Winner - Paul Bisaro '89